Kellman Selected as FSP on Globeimmune Trials

October 27, 2011

Company News Release

Kellman Pharmaceutical Services is now working with GlobeImmune as a Functional Service Provider (FSP). GlobeImmune Inc is a private company developing therapeutic vaccines called Tarmogens for the treatment of cancer and infectious diseases. As a FSP, KPS is providing more efficient data management and cost containment expertise through more efficient data monitoring and reporting.

“We were brought in to provide a more efficient monitoring alternative and are succeeding,” explains KPS President David Kelly. “We look forward to expanding our relationship and scope of services for the company in the future.”